AngioDynamics (ANGO) vs Delcath Systems (DCTH)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 8, 2026.
Summary
Delcath Systems (DCTH) has outperformed AngioDynamics (ANGO) over the past year, gaining 42.4% versus a gain of 28.4%. Over five years, DCTH leads with a +63.4% price change compared with -48.2% for ANGO. Delcath Systems is the larger company by market cap ($507.6 million vs $479.8 million), about 1.1 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | ANGO | DCTH |
|---|---|---|
| Share price | $11.41 | $14.63 |
| Market cap | $479.84M | $507.64M |
| 1-day change | -19.59% | -4.88% |
| YTD return | +10.51% | +52.28% |
| 1-year return | +28.42% | +42.41% |
| 5-year return | -48.15% | +63.44% |
| Forward P/E | — | 325.11 |
| EPS (TTM) | $-0.88 | $0.01 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $16.29 | $17.42 |
| 52-week low | $9.39 | $8.12 |
| Distance from 52-week high | -29.96% | -16.02% |
| Analyst consensus | none | none |
| Avg. price target upside | +75.28% | +64.05% |
| Average volume | 514.11K | 478.44K |
| Shares outstanding | 42.05M | 34.70M |
| Employees | 632 | 156 |
| Sector | Health Care | Health Care |
| Industry | Medical/Dental Instruments | Medical/Dental Instruments |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- DCTH has outperformed ANGO by 14.0 percentage points over the past year.
About AngioDynamics
ANGO stock →AngioDynamics, Inc., a medical technology company, designs, manufactures, and sells products for the treatment of cardiovascular disease and cancer diagnoses in the United States and internationally. The company operates through Med Tech and Med Device segments.
Health Care · Medical/Dental Instruments · 632 employees
About Delcath Systems
DCTH stock →Delcath Systems, Inc., an interventional oncology company, focuses on the treatment of primary and metastatic liver cancers in the United States and Europe. The company's lead product candidate is HEPZATO KIT, a melphalan for injection/hepatic delivery system to administer high-dose chemotherapy to the liver while controlling systemic exposure and associated side effects.
Health Care · Medical/Dental Instruments · 156 employees
ANGO vs DCTH FAQ
Which is bigger, AngioDynamics or Delcath Systems?
Delcath Systems (DCTH) is larger, with a market capitalization of $507.64M compared with $479.84M for AngioDynamics (ANGO).
Which stock has performed better over the past year, ANGO or DCTH?
DCTH returned +42.41% over the past 12 months, compared with +28.42% for ANGO (price return, excluding dividends). Past performance does not predict future results.
Are AngioDynamics and Delcath Systems in the same industry?
Yes. Both are classified in the Medical/Dental Instruments industry within the Health Care sector.